专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08460894B2 Calcium-sensing receptor 2 (CaR2) and methods for using 有权
标题翻译：钙感受体2（CaR2）和使用方法
公开(公告)号：US08460894B2
公开(公告)日：2013-06-11
申请号：US12482702
申请日：2009-06-11
申请人： George Mbella Ekema , Pieter W. Faber , Benjamin Philip Faga , Gregory B. Foust , John Joseph Harrington , Paul David Jackson , Robert W. Mays
发明人： George Mbella Ekema , Pieter W. Faber , Benjamin Philip Faga , Gregory B. Foust , John Joseph Harrington , Paul David Jackson , Robert W. Mays
IPC分类号： C12P21/06 , C12N15/06 , C07K1/00 , C07H21/02
CPC分类号： G01N33/5044 , A61K38/00 , C07H21/04 , C07K14/705 , G01N33/5008 , G01N33/502 , G01N33/5091 , G01N33/6872 , G01N2500/10
摘要： The current disclosure provide a novel human calcium sensing receptor named CaR2 and the nucleotide sequence that encodes the receptor. The disclosure further provides antibodies specific for CaR2. Also disclosed are methods of identifying modulators of the receptor and methods of using the identified modulators to treat calcium receptor mediated conditions.
摘要翻译：目前的公开提供了一种名为CaR2的新型人体钙感觉受体和编码受体的核苷酸序列。本公开进一步提供对CaR2特异性的抗体。还公开了鉴定受体调节剂的方法和使用鉴定的调节剂治疗钙受体介导的病症的方法。

2. 发明申请

US20110318313A1 Modulation of Splenocytes in Cell Therapy for Traumatic Brain Injury 审中-公开
标题翻译：脾细胞在创伤性脑损伤细胞治疗中的调控
公开(公告)号：US20110318313A1
公开(公告)日：2011-12-29
申请号：US13150481
申请日：2011-06-01
申请人： Charles S. Cox, JR. , Robert W. Mays
发明人： Charles S. Cox, JR. , Robert W. Mays
IPC分类号： A61K35/12 , A61P25/00 , C12N5/00 , A61P29/00
CPC分类号： A61K35/545 , A61K35/28 , A61K35/30 , C12N5/0607
摘要： The invention provides methods for treating traumatic brain injury. The invention is generally directed to treating traumatic brain injury by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
摘要翻译：本发明提供治疗创伤性脑损伤的方法。本发明一般涉及通过在受伤的受试者中施用具有一种或多种以下作用的细胞来治疗创伤性脑损伤：与脾细胞相互作用，保持脾脏质量，增加CD4 +和CD8 + T细胞的增殖，增加IL-4和 IL-10，并在损伤部位增加M2：M1巨噬细胞比例。本发明还涉及用于筛选调节细胞具有这些作用的能力的药剂的药物发现方法。本发明还涉及可用于提供用于给予受试者的细胞的细胞库，所述细胞库包含具有用于实现这些作用的所需效力的细胞。

3. 发明申请

US20110293642A1 Modulation of Splenocytes in Cell Therapy 有权
标题翻译：细胞治疗中脾细胞的调节
公开(公告)号：US20110293642A1
公开(公告)日：2011-12-01
申请号：US13150491
申请日：2011-06-01
申请人： Robert W. Mays
发明人： Robert W. Mays
IPC分类号： A61K35/12 , A61P37/04 , G01N33/566 , A61P29/00 , C12Q1/02 , C40B30/04
CPC分类号： A61K35/28 , A61K35/545 , C12N5/0607 , G01N33/5047 , G01N33/505 , G01N33/6893 , G01N2333/5406 , G01N2333/5412 , G01N2333/5428 , G01N2333/545 , G01N2333/70514 , G01N2333/70517 , G01N2500/00 , G01N2800/24 , G01N2800/52
摘要： The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1β, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
摘要翻译：本发明提供了治疗与不良炎症成分相关的病理状况的方法。本发明一般涉及通过在受伤的受试者中施用具有一种或多种以下作用的细胞来减少炎症：与脾细胞相互作用，保持脾脏质量，增加CD4 +和CD8 + T细胞的增殖，增加IL-4和IL- 10，减少IL-6和IL-1和bgr，并在损伤部位增加M2：M1巨噬细胞比例。本发明还涉及用于筛选调节细胞具有这些作用的能力的药剂的药物发现方法。本发明还涉及可用于提供用于给予受试者的细胞的细胞库，所述细胞库包含具有用于实现这些作用的所需效力的细胞。

4. 发明申请

US20100008890A1 MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment 审中-公开
标题翻译：无辅助免疫抑制治疗的MAPC治疗
公开(公告)号：US20100008890A1
公开(公告)日：2010-01-14
申请号：US12161893
申请日：2007-01-23
申请人： Robert W. Mays , Robert J. Deans
发明人： Robert W. Mays , Robert J. Deans
IPC分类号： A61K35/50
CPC分类号： A61K35/50 , A61K31/4353 , A61K31/436 , A61K31/485 , A61K31/52 , A61K31/661 , A61K35/12 , A61K35/28 , A61K35/30 , A61K35/407 , A61K35/44 , A61K35/48 , A61K35/51 , A61K35/545 , A61K38/13 , A61K45/06 , C12N5/0607 , A61K2300/00
摘要： The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.
摘要翻译：本发明涉及用MAPC治疗各种损伤，障碍，功能障碍，疾病等，而不需要辅助性免疫抑制治疗。

5. 发明申请

US20160282336A1 Modulation of Microglia Activation 审中-公开
标题翻译：调节小胶质细胞激活
公开(公告)号：US20160282336A1
公开(公告)日：2016-09-29
申请号：US14857485
申请日：2015-09-17
申请人： Jason A. Hamilton , Anthony E. Ting , Robert W. Mays
发明人： Jason A. Hamilton , Anthony E. Ting , Robert W. Mays
IPC分类号： G01N33/50
CPC分类号： G01N33/5058 , A61K35/28 , C12Q1/68 , G01N33/5005 , G01N33/5023 , G01N33/53 , G01N2500/04 , G01N2500/10
摘要： The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.
摘要翻译：本发明提供了治疗与不良炎症成分相关的病理状况的方法。本发明一般涉及通过施用调节小胶质细胞活化的细胞来减少炎症。本发明还涉及用于筛选调节细胞调节小胶质细胞活化能力的试剂的药物发现方法。本发明还涉及可用于提供用于给予受试者的细胞的细胞库，所述细胞库包含具有期望水平的效力以调节小神经胶质细胞活化的细胞。

6. 发明申请

US20160256502A1 Modulation of Splenocytes in Cell Therapy for Traumatic Brain Injury 审中-公开
标题翻译：脾细胞在创伤性脑损伤细胞治疗中的调控
公开(公告)号：US20160256502A1
公开(公告)日：2016-09-08
申请号：US15064180
申请日：2016-03-08
申请人： Charles Samuel COX , Robert W. Mays
发明人： Charles Samuel COX , Robert W. Mays
IPC分类号： A61K35/545 , C12N5/074
CPC分类号： A61K35/545 , A61K35/28 , A61K35/30 , C12N5/0607
摘要： The invention provides methods for treating traumatic brain injury. The invention is generally directed to treating traumatic brain injury by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
摘要翻译：本发明提供治疗创伤性脑损伤的方法。本发明一般涉及通过在受伤的受试者中施用具有一种或多种以下作用的细胞来治疗创伤性脑损伤：与脾细胞相互作用，保持脾脏质量，增加CD4 +和CD8 + T细胞的增殖，增加IL-4和 IL-10，并在损伤部位增加M2：M1巨噬细胞比例。本发明还涉及用于筛选调节细胞具有这些作用的能力的药剂的药物发现方法。本发明还涉及可用于提供用于给予受试者的细胞的细胞库，所述细胞库包含具有用于实现这些作用的所需效力的细胞。

7. 发明申请

US20110293578A1 Use of Stem Cells to Prevent Neuronal Dieback 审中-公开
标题翻译：使用干细胞预防神经损伤
公开(公告)号：US20110293578A1
公开(公告)日：2011-12-01
申请号：US13062343
申请日：2009-09-04
申请人： Sarah A. Busch , Kevin P. Horn , Robert W. Mays , Jerry Silver
发明人： Sarah A. Busch , Kevin P. Horn , Robert W. Mays , Jerry Silver
IPC分类号： A61K35/12 , C12N5/079 , A61P25/16 , A61P25/00 , A61P25/28 , A61P25/08 , A61K38/18 , C12N5/0786
CPC分类号： A61K35/28 , A61K35/12 , A61K35/30 , A61K35/545 , A61K2035/124 , C12N5/0607
摘要： The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons.
摘要翻译：本发明一般涉及神经元损伤的治疗。特别地，本发明旨在减少由于活化的巨噬细胞与神经系统急性或慢性损伤期间产生的营养不良轴突的相互作用而发生的轴突回缩（“死亡”）。本发明还涉及促进轴突生长/再生。本发明特别涉及使用干细胞或其分泌的细胞因子，例如将在条件细胞培养基中产生的，以改善或预防轴突死亡和/或促进轴突的生长/再生。

8. 发明申请

US20080194021A1 Use of a Gsk-3 Inhibitor to Maintain Potency of Culture Cells 审中-公开
标题翻译：使用Gsk-3抑制剂维持培养细胞的效力
公开(公告)号：US20080194021A1
公开(公告)日：2008-08-14
申请号：US11996890
申请日：2006-07-31
申请人： Robert W. Mays
发明人： Robert W. Mays
IPC分类号： C12N5/06
CPC分类号： C12N5/0607 , C12N2501/40 , C12N2501/415
摘要： The present invention is directed to the culture of non-embryonic cells, that can differentiate into cell types of more than one embryonic lineage, in culture under conditions that maintain differentiation capacity during expansion; more particularly, culturing non-embryonic cells in the presence of at least one GKS-3 inhibitor, such as BIO.
摘要翻译：本发明涉及在扩展期间维持分化能力的条件下培养的非胚胎细胞的培养物，其可以分化成多于一种胚胎谱系的细胞类型; 更具体地，在存在至少一种GKS-3抑制剂如BIO的情况下培养非胚胎细胞。

9. 发明申请

US20150093364A1 USE OF STEM CELLS TO PREVENT NEURONAL DIEBACK 审中-公开
标题翻译：使用干细胞来预防神经元损伤
公开(公告)号：US20150093364A1
公开(公告)日：2015-04-02
申请号：US14561912
申请日：2014-12-05
申请人： Sarah A. BUSCH , Kevin P. Horn , Robert W. Mays , Jerry Silver
发明人： Sarah A. BUSCH , Kevin P. Horn , Robert W. Mays , Jerry Silver
IPC分类号： A61K35/28
CPC分类号： A61K35/28 , A61K35/12 , A61K35/30 , A61K35/545 , A61K2035/124 , C12N5/0607
摘要： The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons.
摘要翻译：本发明一般涉及神经元损伤的治疗。特别地，本发明旨在减少由于活化的巨噬细胞与神经系统急性或慢性损伤期间产生的营养不良轴突的相互作用而发生的轴突回缩（“死亡”）。本发明还涉及促进轴突生长/再生。本发明特别涉及使用干细胞或其分泌的细胞因子，例如将在条件细胞培养基中产生的，以改善或预防轴突死亡和/或促进轴突的生长/再生。

10. 发明授权

US09937208B2 Modulation of splenocytes in cell therapy 有权
公开(公告)号：US09937208B2
公开(公告)日：2018-04-10
申请号：US13150491
申请日：2011-06-01
申请人： Robert W. Mays
发明人： Robert W. Mays
IPC分类号： A61K38/00 , C12N5/00 , A61K35/28 , A61K35/545 , C12N5/074 , G01N33/50 , G01N33/68
CPC分类号： A61K35/28 , A61K35/545 , C12N5/0607 , G01N33/5047 , G01N33/505 , G01N33/6893 , G01N2333/5406 , G01N2333/5412 , G01N2333/5428 , G01N2333/545 , G01N2333/70514 , G01N2333/70517 , G01N2500/00 , G01N2800/24 , G01N2800/52
摘要： The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1β, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式